FDAWed Nov 12, 2025
In the five trading days before ARTV's news on Nov 12 (safety and translational data: AlloNK® + rituximab), traders made no large options trades, and nothing else leaned either way. Foreshadow rates that about normal: 0 out of 100. Options were pricing in a move of about 4.0%. The stock rose 10.9%, and the bets didn't lean either way.
That betting was busier than 0% of 587 finished FDA cases.
The line is the stock price. Under it is each measurement that goes into the score. The yellow days are the five that count; the faded ones show what's normal for this stock. The number at the right of each row is how many of the 100 points it added.
Watch the betting build up, one trading day at a time.
No large options trades were flagged in these five days.
Each measurement is compared with this stock's normal 60 days. The further above normal, the more points it earns, up to its maximum. The points add up to the score. For the formula, see How it works.
How much was bet
$0/day vs $0 normally, 0 vs 0 alerts/day, 0% sweeps
+0.0 of 25
How one-sided the bets were
net ask-side +$0/day vs +$0, calls $0, puts $0
+0.0 of 20
New contracts opened
0 contracts/day vs 0, calls +0, puts +0
+0.0 of 20
Of 37 finished FDA cases that scored 0 to 8, the bets were right in 1 (3%).
Hover over a day to see its numbers, or select the chart and use the arrow keys.
Options volume vs. normal
0th percentile on average, peak 0, baseline 0
+0.0 of 15
Change in the cost of protection
put−call IV 0.0 → 0.0 pts, typical 5-day move ±0.0
+0.0 of 10
Big off-exchange stock trades
$0/day in prints ≥ $1M vs $0, 0 prints
+0.0 of 10
Built from seven kinds of Unusual Whales data for ARTV: large options trades (flow alerts), new open interest, options volume, the put and call price gap (skew), dark-pool prints, daily prices and the expected move. What each one measures
Short answers from this case's data and Unusual Whales, written by Claude.